Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
Tomas KalincikEva Kubala HavrdovaDana HorakovaGuillermo IzquierdoAlexandre PratMarc GirardPierre DuquettePierre GrammondMarco OnofrjAlessandra LugaresiSerkan OzakbasLudwig KapposJens KuhleMurat TerziJeannette Lechner-ScottCavit BozFrancois Grand'MaisonJulie PrevostPatrizia SolaDiana FerraroFranco GranellaMaria TrojanoRoberto BergamaschiEugenio PucciRecai TurkogluPamela A McCombeVincent Van PeschBart Van WijmeerschClaudio SolaroCristina Ramo-TelloMark SleeRaed AlroughaniBassem YamoutVahid ShaygannejadDaniele SpitaleriJosé Luis Sánchez-MenoyoRadek AmpapaSuzanne HodgkinsonRana KarabudakErnest ButlerSteve VucicVilija G JokubaitisTim SpelmanHelmut ButzkuevenPublished in: Journal of neurology, neurosurgery, and psychiatry (2019)
The effect of fingolimod on relapse frequency was superior to teriflunomide and dimethyl fumarate. The effect of the three oral therapies on disability outcomes was similar during the initial 2.5 years on treatment. Persistence on fingolimod was superior to the two comparator drugs.